Table 1 General characteristics of women sampled in each phase, based on woman-years contributed to each sample phase (proportion (%) or median (IQR))
Characteristicsa | EMR (1st phase) | Chart review (2nd phase) | Telephone interview (3rd phase) |
|---|---|---|---|
Total women-years, total number of women | 170,844.6, 85,324 | 16,989.8, 4971 | 5636.9, 1243 |
Number of observations per woman (median (IQR)) | 4.0 (2.0–7.0) | 3.0 (2.0–4.0) | 4.0 (3.0–5.0) |
Total observation time per woman in years (median (IQR)) | 2.0 (0.5–3.4) | 3.9 (2.5–4.6) | 4.6 (4.2–5.0) |
Age at the start of the observation period (median (IQR)) | 33.3 (28.0–38.5) | 31.3 (27.1–35.9) | 30.8 (27.1–35.1) |
Contraceptive method | |||
Implant | 11,978.6 (7.0) | 6694.6 (39.4) | 2151.7 (38.2) |
DMPA | 22,749.3 (13.3) | 4228.4 (24.9) | 988.7 (17.5) |
OCP | 2252.7 (1.3) | 333.7 (2.0) | 88.3 (1.6) |
MEC | 6814.4 (4.0) | 790.6 (4.7) | 157.3 (2.8) |
LEC | 41,237.0 (24.1) | 1643.5 (9.7) | 303.9 (5.4) |
No method | 82,939.8 (48.6) | 3299.0 (19.4) | 1940.6 (34.4) |
Missing | 2872.8 (1.7) | 0.0 (0.0) | 6.4 (0.1) |
ART regimen | |||
Nevirapine-containing | 83,435.5 (48.8) | 7889.4 (46.4) | 2068.4 (36.7) |
Efavirenz-containing | 42,170.2 (24.7) | 5015.0 (29.5) | 1352.2 (24.0) |
PI-containing | 10,044.0 (5.9) | 1206.4 (7.1) | 355.5 (6.3) |
No ART | 31,928.3 (18.7) | 2843.7 (16.7) | 1671.7 (29.7) |
Others | 202.8 (0.1) | 30.6 (0.2) | 14.3 (0.3) |
ART unknown | 0.0 (0.0) | 4.7 (0.0) | 173.3 (3.1) |
Missing | 3063.8 (1.8) | 0.0 (0.0) | 1.5 (0.0) |
Education level | |||
Completed college | 1228.4 (0.7) | 44.9 (0.3) | 9.2 (0.2) |
Some college/university | 5482.1 (3.2) | 570.5 (3.4) | 255.8 (4.5) |
Completed secondary | 16,106.7 (9.4) | 1164.3 (6.9) | 398.1 (7.1) |
Some secondary | 19,938.6 (11.7) | 1928.2 (11.4) | 636.1 (11.3) |
Completed primary | 23,696.3 (13.9) | 2312.3 (13.6) | 595.2 (10.6) |
Some primary | 59,825.4 (35.0) | 6352.7 (37.4) | 1555.6 (27.6) |
None | 696.1 (0.4) | 14.7 (0.1) | 5.0 (0.1) |
Missing | 43,871.1 (25.7) | 4602.2 (27.1) | 2182.0 (38.7) |
Marital status | |||
Not married but living with a partner | 1612.2 (0.9) | 184.1 (1.1) | 62.1 (1.1) |
Never married and not living with a partner | 18,649.0 (10.9) | 1003.5 (5.9) | 301.2 (5.3) |
Separated/divorced | 17,239.8 (10.1) | 1636.8 (9.6) | 705.4 (12.5) |
Legally married | 82,097.1 (48.1) | 9950.0 (58.6) | 3097.7 (55.0) |
Widowed | 28,082.3 (16.4) | 1786.3 (10.5) | 450.2 (8.0) |
Missing | 23,164.2 (13.6) | 2429.1 (14.3) | 1020.3 (18.1) |
Number of living children | |||
0 | 1598.6 (9.4) | 23,360.3 (13.7) | 1758.6 (31.2) |
1+ | 11,039.0 (65.0) | 94,781.3 (55.5) | 3878.3 (68.8) |
Missing | 4352.2 (25.6) | 52,703.1 (30.9) | 0.0 (0.0) |
WHO clinical stage | |||
1 | 63,905.1 (37.4) | 7649.5 (45.0) | 2616.4 (46.4) |
2 | 46,840.8 (27.4) | 4696.9 (27.7) | 1584.6 (28.1) |
3 | 48,634.6 (28.5) | 3834.1 (22.6) | 1162.0 (20.6) |
4 | 10,222.6 (6.0) | 787.3 (4.6) | 264.4 (4.7) |
Missing | 1241.6 (0.7) | 21.9 (0.1) | 9.6 (0.2) |
CD4 cell count | |||
Median (IQR) | 428.0 (274.0–609.0) | 484.0 (339.0–679.0) | 494.9 (353.0–678.4) |
< 50 | 2671.8 (1.6) | 97.6 (0.6) | 61.7 (1.1) |
50–199 | 14,597.8 (8.5) | 924.8 (5.4) | 296.1 (5.3) |
200–349 | 32,166.7 (18.8) | 2740.8 (16.1) | 871.6 (15.5) |
350–499 | 41,537.1 (24.3) | 4067.5 (23.9) | 1378.6 (24.5) |
500+ | 67,998.3 (39.8) | 8104.9 (47.7) | 2710.9 (48.1) |
Missing | 11,872.9 (7.0) | 1054.2 (6.2) | 318.0 (5.6) |
Weight (kg) | |||
Median (IQR) | 57.0 (51.1–64.5) | 58.2 (52.5–65.0) | 59.0 (53.0–66.3) |
< 50 | 30,809.0 (18.0) | 2436.3 (14.3) | 730.3 (13.0) |
50–59 | 61,135.7 (35.8) | 6337.3 (37.3) | 2215.3 (39.3) |
60–69 | 47,672.0 (27.9) | 5137.0 (30.2) | 1646.7 (29.2) |
70+ | 30,588.7 (17.9) | 3025.1 (17.8) | 1027.8 (18.2) |
Missing | 639.1 (0.4) | 54.0 (0.3) | 16.8 (0.3) |
BMI (kg/m2) | |||
Median (IQR) | 21.7 (19.6–24.3) | 22.0 (20.1–24.4) | 22.3 (20.1–24.9) |
18.5 (underweight) | 18,702.9 (11.0) | 1384.1 (8.2) | 455.1 (8.1) |
18.5–25 (normal weight) | 100,289.4 (58.7) | 10,900.2 (64.2) | 3492.3 (62.0) |
25–30 (overweight) | 27,602.0 (16.2) | 2943.9 (17.3) | 1048.4 (18.6) |
30+ (obese) | 8490.5 (5.0) | 760.0 (4.5) | 313.3 (5.6) |
Missing | 15,759.9 (9.2) | 1001.6 (5.9) | 327.9 (5.8) |
Active tuberculosis treatment | |||
None | 163,287.5 (95.6) | 15,896.3 (93.6) | 5307.0 (94.2) |
Active | 7557.2 (4.4) | 1093.4 (6.4) | 329.9 (5.9) |
Calendar year | |||
2011 | 67,811.2 (39.7) | 6433.2 (37.9) | 2868.4 (50.9) |
2012 | 49,226.4 (28.8) | 4687.0 (27.6) | 1159.5 (20.6) |
2013 | 32,343.5 (18.9) | 3019.0 (17.8) | 817.0 (14.5) |
2014 | 164,25.0 (9.6) | 2143.6 (12.6) | 550.7 (9.8) |
2015 | 5038.58 (3.0) | 707.0 (4.2) | 241.3 (4.3) |